Shahab Zaidi, MD
Endocrinology, Diabetes & Metabolism · Zionsville, INNPI 1346457660
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,073 of the $2,977 with a category attached, or 69.6%. It is spread thinly across 27 manufacturers, the largest accounting for just 15.5%.
Across 112 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$460
- Abbott$418
- Chiesi USA, Inc.$300
- Amgen$231
- Lilly USA, LLC$193
- Medtronic$136
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$66022%
- Food & beverage$2,07370%
- Education$140%
- Other$2308%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 19 | $460 |
| Abbott | 14 | $418 |
| Chiesi USA, Inc. | 1 | $300 |
| Amgen(2 entities) | 14 | $231 |
| Lilly USA, LLC | 6 | $193 |
| Medtronic | 8 | $136 |
| Tandem Diabetes Care, Inc. | 7 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 2 | $125 |
| Sanofi | 1 | $110 |
| Dexcom, Inc. | 5 | $100 |
| Companion Medical, Inc. | 1 | $99 |
| Boehringer Ingelheim | 4 | $78 |
| Radius Health, Inc. | 4 | $74 |
| Corcept Therapeutics | 4 | $66 |
| Novo Nordisk | 4 | $64 |
| Shire North American Group Inc | 4 | $59 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Novartis | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Pfizer | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,977 in reported general payments places this provider in the 60th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 221 | $231,920 |
| OzempicSemaglutide | 159 | $177,019 |
| TrulicityDulaglutide | 83 | $97,759 |
| FarxigaDapagliflozin Propanediol | 69 | $84,745 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $83,765 |
| Teriparatide | 24 | $72,616 |
| Humalog Kwikpen U-200Insulin Lispro | 33 | $72,421 |
| JardianceEmpagliflozin | 66 | $66,064 |
| Bydureon BciseExenatide Microspheres | 46 | $46,205 |
| TymlosAbaloparatide | 13 | $37,924 |
| Cinacalcet Hcl | 83 | $35,498 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $34,282 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $29,336 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 64 | $28,557 |
| Novolog FlexpenInsulin Aspart | 68 | $26,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $193 | $331,327324 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $64 | $201,719185 claims |
| AstraZenecaFarxiga | $460 | $84,74569 claims |
| Boehringer IngelheimJardiance | $78 | $66,06466 claims |
| Radius Health, Inc.Tymlos | $74 | $37,92413 claims |
| Sanofi-aventis U.S. LLCLantus | $125 | $2,19811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Zionsville
- Dawn AyersZionsville$47K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.